Serum alpha-fetoprotein response can predict prognosis in hepatocellular carcinoma patients undergoing radiofrequency ablation therapy

Omata, 2010, Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma, Hepatol Int, 4, 439, 10.1007/s12072-010-9165-7 Hung, 2010, Fibrosis and AST to platelet ratio index predict post-operative prognosis for solitary small hepatitis B-related hepatocellular carcinoma, Hepatol Int, 4, 691, 10.1007/s12072-010-9213-3 Lee, 2011, Percutaneous cryoablation of small hepatocellular carcinomas using a 17-gauge ultrathin probe, Clin Radiol, 66, 752, 10.1016/j.crad.2011.02.015 Bruix, 2005, Management of hepatocellular carcinoma, Hepatology, 42, 1208, 10.1002/hep.20933 Huang, 2010, A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria, Ann Surg, 252, 903, 10.1097/SLA.0b013e3181efc656 Lencioni, 2010, Loco-regional treatment of hepatocellular carcinoma, Hepatology, 52, 762, 10.1002/hep.23725 Germani, 2010, Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis, J Hepatol, 52, 380, 10.1016/j.jhep.2009.12.004 Lin, 2005, Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less, Gut, 54, 1151, 10.1136/gut.2004.045203 Brunello, 2008, Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial, Scand J Gastroenterol, 43, 727, 10.1080/00365520701885481 N’Kontchou, 2009, Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis, Hepatology, 50, 1475, 10.1002/hep.23181 Tateishi, 2005, Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases, Cancer, 103, 1201, 10.1002/cncr.20892 Hung, 2011, Survival rates are comparable after radiofrequency ablation or surgery in patients with small hepatocellular carcinomas, Clin Gastroenterol Hepatol, 9, 79, 10.1016/j.cgh.2010.08.018 Kim, 2010, Recurrence and treatment pattern in long-term survivors with hepatocellular carcinoma: a comparison between radiofrequency ablation and surgery as a first-line treatment, World J Surg, 34, 1881, 10.1007/s00268-010-0533-1 Kao, 2011, Risk factors for long-term prognosis in hepatocellular carcinoma after radiofrequency ablation therapy: the clinical implication of aspartate aminotransferase-platelet ratio index, Eur J Gastroenterol Hepatol, 23, 528 Livraghi, 2008, Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice?, Hepatology, 47, 82, 10.1002/hep.21933 Choi, 2007, Percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma as a first-line treatment: long-term results and prognostic factors in a large single-institution series, Eur Radiol, 17, 684, 10.1007/s00330-006-0461-5 Wu, 2009, Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma, J Hepatol, 51, 890, 10.1016/j.jhep.2009.07.009 Chen, 2005, Alpha-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma, Aliment Pharmacol Ther, 22, 217, 10.1111/j.1365-2036.2005.02547.x Chan, 2009, New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy, J Clin Oncol, 27, 446, 10.1200/JCO.2008.18.8151 Shao, 2010, Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma, Cancer, 116, 4590, 10.1002/cncr.25257 Riaz, 2009, Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival, J Clin Oncol, 27, 5734, 10.1200/JCO.2009.23.1282 Tsai, 2010, Favorable alpha-fetoprotein decrease as a prognostic surrogate in patients with hepatocellular carcinoma after radiofrequency ablation, J Gastroenterol Hepatol, 25, 605, 10.1111/j.1440-1746.2009.06115.x Bruix, 2001, Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver, J Hepatol, 35, 421, 10.1016/S0168-8278(01)00130-1 Vora, 2009, Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma, Oncologist, 14, 717, 10.1634/theoncologist.2009-0038 Shirabe, 1997, Significance of alpha-fetoprotein levels for detection of early recurrence of hepatocellular carcinoma after hepatic resection, J Surg Oncol, 64, 143, 10.1002/(SICI)1096-9098(199702)64:2<143::AID-JSO10>3.0.CO;2-7 Sherman, 2010, The resurrection of alphafetoprotein, J Hepatol, 52, 939, 10.1016/j.jhep.2010.02.006 Tateishi, 2006, Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers, Hepatology, 44, 1518, 10.1002/hep.21408 Liaw, 1986, Alpha-fetoprotein changes in the course of chronic hepatitis: relation to bridging hepatic necrosis and hepatocellular carcinoma, Liver, 6, 133, 10.1111/j.1600-0676.1986.tb00279.x Therasse, 2000, New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada, J Natl Cancer Inst, 92, 205, 10.1093/jnci/92.3.205 Llovet, 2008, Sorafenib in advanced hepatocellular carcinoma, N Engl J Med, 359, 378, 10.1056/NEJMoa0708857 Riaz, 2011, Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic–pathologic correlation, J Hepatol, 54, 695, 10.1016/j.jhep.2010.10.004 Yamamoto, 2009, Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy, Ann Surg Oncol, 16, 2795, 10.1245/s10434-009-0618-y Baldan, 2006, Percutaneous radiofrequency thermal ablation for hepatocellular carcinoma, Aliment Pharmacol Ther, 24, 1495, 10.1111/j.1365-2036.2006.03136.x Morimoto, 2011, Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization, Cancer, 116, 5452, 10.1002/cncr.25314 Lam, 2008, Incomplete ablation after radiofrequency ablation of hepatocellular carcinoma: analysis of risk factors and prognostic factors, Ann Surg Oncol, 15, 782, 10.1245/s10434-007-9733-9 Kirikoshi, 2009, Outcome of transarterial chemoembolization monotherapy, and in combination with percutaneous ethanol injection, or radiofrequency ablation therapy for hepatocellular carcinoma, Hepatol Res, 39, 553, 10.1111/j.1872-034X.2009.00490.x Fuke, 2008, Predictive factors for distant recurrence of HCV-related hepatocellular carcinoma after radiofrequency ablation combined with chemoembolization, Aliment Pharmacol Ther, 27, 1253, 10.1111/j.1365-2036.2008.03627.x Veltri, 2006, Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC), Eur Radiol, 16, 661, 10.1007/s00330-005-0029-9 Lopez, 2002, Comparison of transarterial chemoembolization in patients with unresectable, diffuse vs focal hepatocellular carcinoma, Arch Surg, 137, 653, 10.1001/archsurg.137.6.653 Seror, 2008, Large (>or=5.0-cm) HCCs: multipolar RF ablation with three internally cooled bipolar electrodes—initial experience in 26 patients, Radiology, 248, 288, 10.1148/radiol.2481071101 Barakat, 2010, Morphological features of advanced hepatocellular carcinoma as a predictor of downstaging and liver transplantation: an intention-to-treat analysis, Liver Transpl, 16, 289, 10.1002/lt.21994